Archive


Category: Deep Dive: Market Access

  • ICSs: improving patient and market access at a local level

    Integrated Care Systems (ICSs) – 42 partnerships of health and care organisations who will plan and deliver more joined-up services for their locality in England from 1 July 2022 – will touch on every issue that is shaping healthcare today. “A lot of things are happening in the environment right now and all of the […]

  • Time is motor neurons – the importance of newborn screening in SMA

    Spinal muscular atrophy (SMA) is a devastating, genetic neuromuscular disease caused by a lack of a functional SMN1 gene that results in the progressive and irreversible loss of motor neurons. SMA affects approximately one in 10,000 live births worldwide. The loss of motor neurons affects muscle functions, like breathing, swallowing, and walking. SMA, though a […]

  • Is it time to rethink electronic prescribing in the US?

    It is a fact of life that most – if not all – patients will require some form of prescription medication during their lifetime. Generally, accessing their assigned medication is relatively straightforward, as non-specialty drugs can be dispensed through various channels, including national retail chains, community retail pharmacies, and mail-order pharmacies. But, for the select […]

  • Closing the digital expectation gap in pharma

    Jan Deman is Takeda’s head of digital customer experience for Europe and Canada. But he’d prefer not to refer to what he does as “innovation”. It’s a word, he says, that doesn’t reflect where pharma stands in relation to larger trends. “It’s not innovation in the usual sense of the word,” Deman says. “Mostly it […]

  • How do we make patient centricity a reality?

    For years, the subject of fostering direct connections with patients has been highlighted by notable figures across the healthcare and life sciences industries as a key feature to be explored in future strategies. The trouble is, when it comes to turning these impassioned ideas into actionable progress, patient centricity has generally been limited to commercial […]

  • Leveraging KOL insights to succeed in a data-driven world

    For years, key opinion leaders (KOLs) have held a position of authority and respect amongst those working across the life science industry, be it a result of their expertise in a specific therapeutic area, notable experience working in a particular field, or their connections with researchers, decision-makers, and patients. In a traditional setting, where face-to-face […]

  • Rethinking value: why diverse viewpoints matter

    Value is a tricky concept to capture accurately. Given the diverse and complex world that we live in, different people will often hold contrasting views of what constitutes value. Identifying and measuring value is a particularly interesting quandary for life sciences companies, as inevitably each of these viewpoints will interact with the industry in some […]

  • Turning words into actions with patient engagement

    Boehringer Ingelheim’s Carinne Brouillon tells us how the company co-created its recent Global Patient Partnership Summit with patients and how the meeting brought representatives together to design actionable projects for pharma-patient engagement. This article appears in our free digital magazine Deep Dive: Market Access 2021. Read a preview below: As pharma seeks new and better […]

  • Turning words into actions with patient engagement

    Boehringer Ingelheim’s Carinne Brouillon tells us how the company co-created its recent Global Patient Partnership Summit with patients and how the meeting brought representatives together to design actionable projects for pharma-patient engagement. This article appears in our free digital magazine Deep Dive: Market Access 2021. Read a preview below: As pharma seeks new and better […]

  • How the patient voice is becoming vital for drug approval

    Rebecca Sanders from Lipodystrophy UK tells us how the patient voice helped convince NICE to approve a much-needed drug for this rare disease, and explores how regulators and pharma companies can help make patient involvement in HTA more impactful. This article appears in our free digital magazine Deep Dive: Market Access 2021. Read below for […]

  • “A long way to go” for digital health reimbursement

    A recent analysis delves into the challenges companies face in getting digital health technologies reimbursed and presents recommendations for how these products can find a smoother path to market. This article appears in our free digital magazine Deep Dive: Market Access 2021. Read a preview below: In many ways, the healthcare sector is still wrestling […]

  • Time for a NICE change

    The National Institute for Health and Care Excellence (NICE) is world-renowned for their work assessing the clinical and cost-effectiveness of new treatments. In recognition of how the world has changed over its history, NICE is coming to the end of a period of review and consultation on their processes and methods. Leela Barham takes stock. […]

  • Rethinking access barriers to innovation

    Market access issues don’t stop once a product has passed HTA – and this is especially true for disruptive therapies like ATMPs. Experts from Executive Insight discuss how a holistic, multi-stakeholder approach can help companies overcome access barriers at all stages. This article appears in our digital magazine Deep Dive: Market Access 2021. Read on […]

  • AI meets RWE: The future of drug assessment?

    Savana’s Dr Ignacio Medrano explains how machine learning and natural language processing technology is opening up huge amounts of previously-inaccessible real-world evidence (RWE) for pharma and regulators. This article appears in out digital magazine Deep Dive: Market Access 2021. Read below for a preview: Real world evidence (RWE) is rapidly evolving. Having gone from being […]

  • Listening to ultra-rare disease communities

    When it comes to ultra-rare diseases, the smaller the patient population, the bigger the challenges. As a global commercial biopharmaceutical company pioneering therapies for ultra-rare diseases, PTC Therapeutics is familiar with the challenges. The company prides itself on a patient-centric approach to treatment but there can be significant hurdles in patients accessing potentially life-changing treatments. […]

  • How to improve payer engagement with tailored value communication

    Pharmaceutical drug success rests on being able to achieve market access. Brands are facing increasing pressure to demonstrate strong value propositions in increasingly crowded therapeutic areas. However, value can mean different things to different payers. In this article, Cecilie Alstad, senior analyst at Research Partnership, discusses how an approach established in the world of marketing […]

  • How will NICE fare in a post-Brexit world?

    NICE has a global reputation as a pioneering HTA – but is that influence at risk now that the UK has left the EU? Experts from ICON give us their views on the past, present and future of NICE’s standing on the world stage. This article appears in our digital magazine, Deep Dive: Market Access […]

  • Research predicts the post-COVID landscape for HCP engagement

    IQVIA’s Liz Murray takes us through the company’s latest research into HCPs’ attitudes to pharma engagement, and asks how pharma sales forces can adapt for future changes. This article appears in full in Deep Dive: Market Access 2021. Read a preview below: Recent ChannelDynamics data from IQVIA shows that while there has been a marked […]

  • A year on: pandemic driven trends in HCP engagement

    IQVIA’s John Procter explores why the industry should be paying attention to the changing HCP customer experience in the wake of COVID-19. This article appears in full in this month’s Deep Dive digital magazine on Market Access. Here is a preview: As we reach the end of the first quarter of 2021, our customers continue […]